237 related articles for article (PubMed ID: 19176392)
1. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
Rao VA; Klein SR; Agama KK; Toyoda E; Adachi N; Pommier Y; Shacter EB
Cancer Res; 2009 Feb; 69(3):948-57. PubMed ID: 19176392
[TBL] [Abstract][Full Text] [Related]
2. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.
Rao VA; Zhang J; Klein SR; Espandiari P; Knapton A; Dickey JS; Herman E; Shacter EB
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1125-34. PubMed ID: 21373894
[TBL] [Abstract][Full Text] [Related]
4. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
Krishan S; Richardson DR; Sahni S
Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21
Moussa RS; Kovacevic Z; Bae DH; Lane DJR; Richardson DR
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):761-774. PubMed ID: 29032246
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
7. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
8. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
9. Iron chelator-induced up-regulation of Ndrg1 inhibits proliferation and EMT process by targeting Wnt/β-catenin pathway in colon cancer cells.
Chen Z; Sun J; Li T; Liu Y; Gao S; Zhi X; Zheng M
Biochem Biophys Res Commun; 2018 Nov; 506(1):114-121. PubMed ID: 30340826
[TBL] [Abstract][Full Text] [Related]
10. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
11. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
12. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
13. Trypanotoxic activity of thiosemicarbazone iron chelators.
Ellis S; Sexton DW; Steverding D
Exp Parasitol; 2015 Mar; 150():7-12. PubMed ID: 25595343
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
[TBL] [Abstract][Full Text] [Related]
15. The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
Gutierrez E; Richardson DR; Jansson PJ
J Biol Chem; 2014 Nov; 289(48):33568-89. PubMed ID: 25301941
[TBL] [Abstract][Full Text] [Related]
16. Complex forming competition and in-vitro toxicity studies on the applicability of di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) as a metal chelator.
Gaál A; Orgován G; Polgári Z; Réti A; Mihucz VG; Bősze S; Szoboszlai N; Streli C
J Inorg Biochem; 2014 Jan; 130():52-8. PubMed ID: 24176919
[TBL] [Abstract][Full Text] [Related]
17. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
[TBL] [Abstract][Full Text] [Related]
18. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
Gutierrez EM; Seebacher NA; Arzuman L; Kovacevic Z; Lane DJ; Richardson V; Merlot AM; Lok H; Kalinowski DS; Sahni S; Jansson PJ; Richardson DR
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1665-81. PubMed ID: 27102538
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerase IIα: novel function of wedelolactone.
Benes P; Knopfova L; Trcka F; Nemajerova A; Pinheiro D; Soucek K; Fojta M; Smarda J
Cancer Lett; 2011 Apr; 303(1):29-38. PubMed ID: 21315506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
